NDA 219379 · Springworks
Gomekli
Mirdametinib · Oral
NovelPriority reviewOrphanCDER novel approval, Feb 11, 2025: To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 11, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
29
0 Phase 3, 13 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 11, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- GOMEKLI · MIRDAMETINIB 3MG · TABLET, FOR SUSPENSION, ORAL · Prescription
- GOMEKLI · MIRDAMETINIB 4MG · TABLET, FOR SUSPENSION, ORAL · Prescription
- GOMEKLI · MIRDAMETINIB 1MG · TABLET, FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mirdametinib" as an intervention, any sponsor and status, largest first.
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaRecruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT04923126 · 132 participants (planned) · Start Jun 21, 2021 · Primary completion Jun 2031
Drug: Mirdametinib · For: Low-Grade Glioma; Recurrent Low-Grade Glioma; Progressive Low-Grade Glioma
Sites: Memphis, Tennessee
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruiting
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyIndustry
NCT03962543 · 114 participants · Start Sep 29, 2019 · Primary completion Sep 20, 2023
Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet · For: Plexiform Neurofibroma; Neurofibromatosis Type 1 (NF1)
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 43 sites in all
PfizerPfizer (PFE)
NCT01347866 · 105 participants · Start Oct 2011 · Primary completion Dec 2015
Drug: PF-05212384; PD-0325901 and 2 more · For: Advanced Cancer
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 18 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03905148 · 91 participants · Start May 1, 2019 · Primary completion Oct 9, 2024
Drug: Lifirafenib; mirdametinib · For: Solid Tumor, Adult
Sites: Santa Monica, California; Houston, Texas; Blacktown, Australia · 6 sites in all
University of OxfordAcademic, hospital or other
NCT02510001 · 82 participants · Start Nov 2014 · Primary completion Dec 3, 2018
Drug: PF-02341066; PD-0325901 and 1 more · For: Solid Tumor; Colorectal Cancer
Sites: Oxford, United Kingdom
PfizerPfizer (PFE)
NCT00147550 · 79 participants · Start Feb 2004 · Primary completion May 2007
Drug: PD-0325901 · For: Melanoma; Colonic Neoplasms; Breast Neoplasms
Sites: Birmingham, Alabama; La Jolla, California; La Mesa, California · 17 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT02022982 · 60 participants · Start Jan 2014 · Primary completion Nov 1, 2017
Drug: Palbociclib; PD-0325901 · For: KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors
Sites: Boston, Massachusetts
- Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNot yet recruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT07521657 · 55 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 1, 2031
Drug: mirdametinib · For: Neurofibromatosis 1 (NF1)
Sites: Birmingham, Alabama
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Moertel CL, Hirbe AC, Shuhaiber HH, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.
Damodharan S, Tonsgard J · PLoS One 2026 · Systematic Review, Meta-Analysis
- NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD, Wolters PL, Plotkin SR, et al. · J Clin Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research.
Wang Z, Huang J, Liu J, et al. · Clin Cancer Res 2026 · Clinical Trial, Phase II
- Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis.
Sanikommu S, Santos AN, Govindarajan V, et al. · Clin Neurol Neurosurg 2026 · Systematic Review, Meta-Analysis
Sponsor: Springworks
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.